Wild-type p53 activates transcription in vitro
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 protein is an important determinant in human cancer and regulates the growth of cells in culture. It is known to be a sequence-specific DNA-binding protein with a powerful activation domain, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair (13).”
From Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism (2010) · cites this paper as [13]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,825
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Research works printed but not linked: 7
- O'Rourke, R. W. et al. Oncogene 5, 1829–1832 (1990).
- Zhu, H., Roy, A. L., Roeder, R. G. & Prywes, R. New Biologist 3, 455–464 (1991).
- Kern, S. E. et al. Oncogene 6, 131–136 (1991).
- Fried, M. & Prives, C. Cancer Cells 4, 1–16 (1986).
- Soussi, T., Caron de Fromentel, C. & May, P. Oncogene 5, 945–952 (1990).
- Murakami, Y., Asano, M., Satake, M. & Ito, Y. Oncogene 5, 5–14 (1990).
- Zambetti, G. P. et al. Genes Dev. (in the press).
Cited by
Items 101–200 of 578
Halazonetis, T. D., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06199.x · Cited by 205
p53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 202
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
Brown, R., Clugston, C., Edlin, A., Vasey, P., Kaye, S. B., Burns, P., & Vojtěšek, B. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550428 · Cited by 202
Tishler, R. B., Calderwood, S. K., Coleman, C. N., & Price, B. D. (1993) · PubMed · Cited by 200
Takenaka, I., Morin, F., Seizinger, B. R., & Kley, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5405 · Cited by 197
Jiang, X.-H., Wong, B. C.-Y., Lin, M. C.-M., Zhu, G.-H., Kung, H.-F., Jiang, S.-H., Yang, D., & Lam, S.-K. (2001) · Oncogene · doi:10.1038/sj.onc.1204981 · Cited by 193
“In transcriptiondependent p53 activation, p53 functions as a site speci®c transcription factor that induces p53-inducible genes such as p21cip1/waf1, bax, gadd45, and mdm2 (Farmer et al., 1992; El-Deiry et al., 1993; Miyashita et al., 1995; Zhu et al., 1999).”
BackgroundViral Oncoproteins Discriminate between p53 and the p53 Homolog p73
Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6316 · Cited by 193
“For example, polyomaviruses, papillomaviruses, and adenoviruses encode T, E6, and E1B 55K proteins, respectively, which bind to and inactivate p53 (1, 3, 8, 11, 16, 19, 26, 30, 32, 40, 42, 49, 51).”
Wild-type p53 adopts a ‘mutant’-like conformation when bound to DNA.
Halazonetis, T. D., Davis, L. J., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05743.x · Cited by 193
Sabbatini, P., Chiou, S.-K., Rao, L., & White, E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.1060 · Cited by 191
“Expression of mutp53, which lacks the ability to activate transcription from constructs containing strong p53-binding sites (12, 14, 22, 23, 62), had no significant effect on the background levels of CAT activity (Fig.”
Backgroundp53 is a general repressor of RNA polymerase III transcription
Cairns, C. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3112 · Cited by 190
“It can bind to DNA in a sequence-specific fashion and stimulate expression of proximal genes (Bargonetti et al., 1991; Kern et al., 1991; Farmer et al., 1992; Zambetti et al., 1992).”
Activation of the cryptic DNA binding function of mutant forms of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 189
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Foster, S. A., Demers, G. W., Etscheid, B. G., & Galloway, D. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5698-5705.1994 · Cited by 160
“One function of p53 that has been elucidated is its ability to act as a transcriptional activator by virtue of its ability to bind specific DNA sequences (2, 9, 10, 21, 36).”
BackgroundDNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53
Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S. P., Pedeux, R., Wang, X. W., Yokota, J., Riabowol, K., & Harris, C. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161151798 · Cited by 185
Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R., & Shenk, T. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.227 · Cited by 182
p53-Mediated Repression of Alpha-Fetoprotein Gene Expression by Specific DNA Binding
Lee, K. C., Crowe, A. J., & Barton, M. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1279 · Cited by 175
“Activation of gene expression by p53 protein has been reconstituted in vitro by transcription in cell-free HeLa extracts (18, 43).”
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
The Transactivation Domains of the p53 Protein
Raj, N., & Attardi, L. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 168
“…by subsequent studies showing that wild-type human and mouse p53 can bind defined DNA elements and activate transcription from specific promoters in in vitro transcription or transfection assays, whereas tumor-derived p53 mutants fail to do so (Farmer et al. 1992; Zambetti et al. 1992).”
Backgroundp53 Expression Induces Apoptosis in Hippocampal Pyramidal Neuron Cultures
Jordán, J., Galindo, M. F., Prehn, J. H. M., Weichselbaum, R. R., Beckett, M., Ghadge, G. D., Roos, R. P., Leiden, J. M., & Miller, R. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01397.1997 · Cited by 167
Proteolysis by Calpains: a Possible Contribution to Degradation of p53
Pariat, M., Carillo, S., Molinari, M., Salvat, C., Debüssche, L., Bracco, L., Milner, J., & Piechaczyk, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2806 · Cited by 165
“Importantly, tumor-derived p53 mutants are no longer able to bind to PREs and to activate transcription (17, 30, 56, 70).”
BackgroundThe specificity of p53 mutation spectra in sunlight induced human cancers
Daya-Grosjean, L., Dumaz, N., & Sarasin, A. (1995) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(95)07130-t · Cited by 164
Gottlieb, E., Haffner, R., von Rüden, T., Wagner, E. F., & Oren, M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06390.x · Cited by 163
p53 domains: structure, oligomerization, and transformation.
Wang, P., Reed, M., Wang, Y., Mayr, G., Stenger, J. E., Anderson, M. E., Schwedes, J. F., & Tegtmeyer, P. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5182 · Cited by 161
“Although the suppression functions of p53 are not completely understood, one mechanism by which p53 acts is the direct activation of transcription via site-specific DNA binding (5, 9, 15).”
BackgroundRegulation and Mechanisms of Mammalian Gene Amplification
(1993) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60956-2 · Cited by 160
Adenovirus E1B 55K Represses p53 Activation In Vitro
Martin, M. E. D., & Berk, A. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3146-3154.1998 · Cited by 159
“The DNA tumor viruses each encode oncoproteins, such as Ad E1B 55K, human papillomavirus E6, and simian virus 40 T antigen (9, 11, 27, 67), which bind to and inhibit the normal biological functions of p53.”
Backgroundp53 represses ribosomal gene transcription
Budde, A., & Grummt, I. (1999) · Oncogene · doi:10.1038/sj.onc.1202402 · Cited by 157
“When linked to a Pol II promoter, the p53 binding site confers p53-dependent transcriptional activation of the respective target gene (Funk et al., 1992; Farmer et al., 1992).”
BackgroundWebster, K., Parish, J. L., Pandya, M. J., Stern, P. L., Clarke, A. R., & Gaston, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.87 · Cited by 176
Zauberman, A., Barak, Y., Ragimov, N., Levy, N., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05941.x · Cited by 173
Interaction of p53 with Its Consensus DNA-Binding Site
Wang, Y., Schwedes, J. F., Parks, D., Mann, K., & Tegtmeyer, P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2157 · Cited by 149
“Indeed, many mutations severely reduce site-specific DNA binding (1, 15) and transactivation in vivo (9, 16, 20).”
BackgroundHardcastle, I. R., Ahmed, S. U., Atkins, H., Farnie, G., Golding, B. T., Griffin, R. J., Guyenne, S., Hutton, C., Källblad, P., Kemp, S. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601194 · Cited by 148
Kunz, C., Pebler, S., Otte, J., & von der Ahe, D. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.18.3710 · Cited by 144
The Role of p53 in Cell Cycle Regulation
Shaw, P. H. (1996) · Pathology - Research and Practice · doi:10.1016/s0344-0338(96)80088-4 · Cited by 169
Marrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z · Cited by 183
Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P. K., Yeargin, J., & Haas, M. (1994) · PubMed Central · Cited by 135
p53 abnormalities in different subtypes of human sarcomas.
Andreassen, Å. K., Øyjord, T., Hovig, E. J., Holm, R., Flørenes, V. A., Nesland, J. M., Myklebost, O., Høie, J., Bruland, Ø. S., & Børresen‐Dale, A. (1993) · PubMed · Cited by 150
Physical and functional interaction between wild-type p53 and mdm2 proteins.
Haines, D. S., Landers, J. E., Engle, L. J., & George, D. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1171 · Cited by 137
Hoppe‐Seyler, F., & Butz, K. (1993) · Journal of Virology · doi:10.1128/jvi.67.6.3111-3117.1993 · Cited by 143
“We believe that the former possibility is more likely, since the transcriptional stimulation of important cellular regulatory genes by p53 has been implicated to play a key role for its function as a tumor suppressor protein and mutant forms of p53 devoid of tumor-suppressive activity generally have lost the ability t…”
BackgroundPrognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006163101948 · Cited by 163
Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53.
Morris, G. F., Bischoff, J. R., & Mathews, M. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.2.895 · Cited by 131
p53 oligomerization and DNA looping are linked with transcriptional activation.
Stenger, J. E., Tegtmeyer, P., Mayr, G. A., Reed, M., Wang, Y., Wang, P., Hough, P. V., & Mastrangelo, I. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06947.x · Cited by 100
Watanabe, T., & Sullenger, B. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150104097 · Cited by 130
Li, J., Wang, X., Diaz, J., Tsang, S. H., Buck, C. B., & You, J. (2013) · Journal of Virology · doi:10.1128/jvi.01216-13 · Cited by 128
“In contrast to MCV LT, expression of SV40 LT, which has been shown to bind to p53 and inhibit its transcriptional activity (53), led to a decrease in p21 protein level compared to the empty vector (Fig.”
BackgroundResultInterference with p53 protein inhibits hematopoietic and muscle differentiation.
Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L., Crescenzi, M., & Sacchi, A. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.1.193 · Cited by 127
“Biochemical and molecular studies demonstrated that p53 is able to bind to specific DNA sequences (Kern et al., 1991) and to activate gene transcription (Farmer et al., 1992).”
BackgroundA temperature‐sensitive mutant of human p53.
Zhang, W., Guo, X. Y., Hu, G., Liu, W. B., Shay, J. W., & Deisseroth, A. B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06543.x · Cited by 139
Waterman, J. L. F., Shenk, J. L., & Halazonetis, T. D. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07027.x · Cited by 144
Nevels, M. M., Rubenwolf, S., Spruß, T., Wolf, H. J., & Dobner, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1206 · Cited by 124
Teodoro, J. G., & Branton, P. E. (1997) · Journal of Virology · doi:10.1128/jvi.71.5.3620-3627.1997 · Cited by 149
“p53 is a transcription factor which can both activate and repress gene expression (19, 24, 64, 79).”
Backgroundp53 tetramerization: at the center of the dominant-negative effect of mutant p53
Gencel-Augusto, J., & Lozano, G. (2020) · Genes & Development · doi:10.1101/gad.340976.120 · Cited by 124
“Many assays take advantage of overexpression systems to examine a role for mutant p53 in inhibiting WT p53 activity (Lavigueur et al. 1989; Farmer et al. 1992; Kern et al. 1992; Harvey et al. 1995; Hegi et al. 2000; Klein et al. 2000; Chan et al. 2004; Xu et al. 2011; Aubrey et al. 2018;Walerych et…”
BackgroundUnger, T., Mietz, J. A., Scheffner, M., Yee, C. L., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.9.5186 · Cited by 123
Chen, X., Farmer, G., Zhu, H., Prywes, R., & Prives, C. (1993) · Genes & Development · doi:10.1101/gad.7.10.1837 · Cited by 123
Tyrosinase Gene Expression is Regulated by p53
Khlgatian, M. K., Hadshiew, I., Asawanonda, P., Yaar, M., Eller, M. S., Gilchrest, B. A., Fujita, M., & Norris, D. A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01667.x · Cited by 130
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
Margulies, L., & Sehgal, P. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82442-5 · Cited by 119
p53: A Cell Cycle Regulator Activated by DNA Damage
Selivanova, G., & Wiman, K. G. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60253-5 · Cited by 129
Tumor-suppressor p53 and the cell cycle
Perry, M. E., & Levine, A. J. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80340-5 · Cited by 118
Tumourigenesis associated with the p53 tumour suppressor gene
Chang, F., Syrjänen, S., Tervahauta, A. I., & Syrjänen, K. J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.404 · Cited by 143
Binding Induced Folding in p53−MDM2 Complex
Chen, H., & Luo, R. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0678774 · Cited by 120
Yan, Y., Shay, J. W., Wright, W. E., & Mumby, M. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15220 · Cited by 116
The Role of the p53 Tumor Suppressor Gene in Squamous Cell Carcinoma of the Head and Neck
Field, J. K., Pavelić, Z. P., Spandidos, D. A., Stambrook, P. J., Jones, A., & Gluckman, J. L. (1993) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1993.01880220064009 · Cited by 127
p53 Inhibits RNA Polymerase III-Directed Transcription in a Promoter-Dependent Manner
Chesnokov, I., Chu, W.-M., Botchan, M. R., & Schmid, C. W. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.7084 · Cited by 114
“One hundred nanograms of wild-type (wt) p53 (lane 2), GST (lane 3), GST-p53(1-73) (lane 4), or GST-p53(22,23) (lane 5) was preincubated with nuclear extract before addition of the plasmid with the Alu-T insertion.”
BackgroundMethodInfluentialProapoptotic BAX and BAK control multiple initiator caspases
Ruiz‐Vela, A., Opferman, J. T., Cheng, E. H., & Korsmeyer, S. J. (2005) · EMBO reports · doi:10.1038/sj.embor.7400375 · Cited by 113
“We have used WT, DKO, Casp-9 / and Apaf-1 / MEFs immortalized by SV40, which inhibits the transcriptional activity of p53 and therefore blocks all the possible downstream targets (Farmer et al, 1992).”
MethodThe transforming activity of simian virus 40 large tumor antigen
Manfredi, J. J., & Prives, C. L. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90006-x · Cited by 130
Absence of p53 Gene Mutations in Cutaneous Melanoma
Lübbe, J., Reichel, M., Burg, G., & Kleihues, P. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12381544 · Cited by 122
Oxidative stress is involved in the UV activation of p53
Renzing, J., Hansen, S., & Lane, D. P. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.5.1105 · Cited by 113
The tumor suppressor p53 regulates its own transcription.
Deffie, A., Wu, H., Reinke, V, & Lozano, G. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3415 · Cited by 112
Human Cytomegalovirus Immediate-Early Protein IE2 Tethers a Transcriptional Repression Domain to p53
Tsai, H.-L., Kou, G. H., Chen, S.-C., Wu, C., & Lin, Y.-S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3534 · Cited by 119
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90014-0 · Cited by 135
Wu, L., Bayle, J. H., Elenbaas, B., Pavletich, N. P., & Levine, A. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.497 · Cited by 108
“The tumor suppressor gene product p53 functions as a transcription factor (9, 17, 44) that can positively or negatively regulate a set of genes (11, 32).”
Backgroundp53 binds to the TATA-binding protein-TATA complex
Martin, D. W., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38619-3 · Cited by 107
Milne, D. M., Palmer, R. H., & Meek, D. W. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.21.5565 · Cited by 107
Sun, X., Shimizu, H., & Yamamoto, K.-I. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4489 · Cited by 122
Base transitions are the most frequent genetic changes at P53 in gastric cancer.
Renault, B., van den Broek, M., Fodde, R., Wijnen, J., Pellegata, N. S., Amadori, D., Khan, P. M., & Ranzani, G. N. (1993) · PubMed · Cited by 105
Focal Adhesion Kinase and p53 Signaling in Cancer Cells
Golubovskaya, V., & Cance, W. G. (2007) · International review of cytology · doi:10.1016/s0074-7696(07)63003-4 · Cited by 118
Canman, C. E., & Kastan, M. B. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)61068-6 · Cited by 117
Elledge, R. M., & Lee, W. (1995) · BioEssays · doi:10.1002/bies.950171105 · Cited by 118
Cesarman, E., Inghirami, G. G., Chadburn, A., & Knowles, D. M. (1993) · PubMed · Cited by 117
Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., & Epstein, C. B. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb12115.x · Cited by 116
Kramm, C. M., Sena‐Esteves, M., Barnett, F. H., Rainov, N. G., Schuback, D. E., Yu, J. S., Pechan, P. A., Paulus, W., Chiocca, E. A., & Breakefield, X. O. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00615.x · Cited by 108
McCarthy, S. A., Symonds, H., & Dyke, T. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3979 · Cited by 116
p53 is covalently linked to 5.8S rRNA.
Fontoura, B. M., Sorokina, E. A., David, E., & Carroll, R. B. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5145 · Cited by 102
Datta, B., Li, B., Choubey, D., Nallur, G., & Lengyel, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27544 · Cited by 102
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 99
Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia.
Kim, S. H., Roth, K. A., Moser, A. R., & Gordon, J. I. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.4.877 · Cited by 99
“p53 is thought to play an important role in regulating cellular proliferation, differentiation, and survival: (a) effects on the cell cycle have been demonstrated in normal and transformed cells (5, 6, 18, 38, 45, 49, 52, 68, 71); (b) it can regulate the activities of a variety of promoters, including those that may b…”
BackgroundExpression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer
Duan, W., Gao, L., Druhan, L. J., Zhu, W., Morrison, C., Otterson, G. A., & Villalona-Calero, M. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh292 · Cited by 99
Adenovirus E1B 55-Kilodalton Oncoprotein Inhibits p53 Acetylation by PCAF
Liu, Y., Colosimo, A. L., Yang, X.-J., & Liao, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5540-5553.2000 · Cited by 97
“This interaction interferes with sequence-specific DNA binding of p53 and therefore inhibits p53-mediated transcriptional transactivation (2, 10, 41).”
BackgroundHansen, S., Hupp, T. R., & Lane, D. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3917 · Cited by 94
“The N-terminal domain functions as a transcriptional activator (Fields and Jang, 1990; Raycroft et al., 1990; Farmer et al., 1992; Unger et al., 1992), and the C terminus has been shown to contain a tetramerization domain (Shaulian et al., 1992; Clore et al., 1994; Waterman et al., 1995) and to…”
BackgroundSoini, Y., Turpeenniemi-Hujanen, T. M., Kamel, D., Autio‐Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Pääkkö, P. K., & Vähäkangas, K. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.475 · Cited by 95
Sakorafas, G. H., Tsiotou, A. G., & Tsiotos, G. G. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0144 · Cited by 103
p53 and c‐erbB‐2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder
Kamel, D., Pääkkö, P. K., Nuorva, K., Vähäkangas, K., & Soini, Y. (1993) · The Journal of Pathology · doi:10.1002/path.1711700111 · Cited by 94
Saxena, A., Clark, W. C., Robertson, J. T., Ikejiri, B. L., Oldfield, E. H., & Ali, I. U. (1992) · PubMed · Cited by 94
Ullrich, S. J., Sakaguchi, K., Lees-Miller, S. P., Fiscella, M., Mercer, W. E., Anderson, C. W., & Appella, E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5954 · Cited by 93
Sullivan, K. D., Gallant-Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 91
“[13–17].”
The p53 tumor suppressor protein regulates hematopoietic stem cell fate
Asai, T., Liu, Y., Bae, N., & Nimer, S. D. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22561 · Cited by 111
“In addition, p53mutations are found in 25% of blast phase chronic myelogenous leukemia (Kelman et al., 1989; Feinstein et al., 1991), generally accompanying disease progression (Ahuja et al., 1989).”
Backgroundp53 Regulates the Minimal Promoter of the Human Topoisomerase II Gene
Sandri, M. I., Isaacs, R. J., Ongkeko, W. M., Harris, A. L., Hickson, I. D., Broggini, M., & Vikhanskaya, F. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.22.4464 · Cited by 91
The p53 and mdm‐2 genes in human testicular germ‐cell tumors
Riou, G., Barrois, M., Prost, S., Terrier, M. J., Theodore, C., & Levine, A. J. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940120303 · Cited by 91
Galatin, P. S., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm034182u · Cited by 90
Nagaich, A. K., Appella, E., & Harrington, R. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14842 · Cited by 89
Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans
Mashberg, A., Boffetta, P., Winkelman, R., & Garfinkel, L. (1993) · Cancer · doi:10.1002/1097-0142(19930815)72:4<1356::aid-cncr2820720434>3.0.co;2-0 · Cited by 403
Tumor Suppressor p53 Mutations and Breast Cancer: A Critical Analysis
Ozbun, M. A., & Butel, J. S. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60252-3 · Cited by 103
Mandal, S., Freije, W. A., Guptan, P., & Banerjee, U. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200912024 · Cited by 85
“Processing by the ubiquitin–proteasome system involves the covalent attachment of ubiquitin molecules to the target protein followed by its degradation by the proteasome (Hershko, 2005).”
Metadata
- Authors
- Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C.
- Affiliations
- Columbia University (US)
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063158632
- Cited by
- 579
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 38.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, transcriptional activation, wild-type p53, mutant p53, SV40 large T antigen, DNA-binding proteins, tumour suppressor, protein-protein interaction, transcriptional repression
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, DNA Mutational Analysis, DNA-Binding Proteins, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Structure-Activity Relationship, Transcription Factors, Transcription, Genetic, Tumor Suppressor Protein p53, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.